Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy

American Journal of Medicine

Volumn 101, Issue 1, 1996, Pages 68-76

  Heldman, Alan W ^a   Hartert, Tina V ^a   Ray, Stuart C ^a   Daoud, Emile G ^a   Kowalski, Thomas E ^a   Pompili, Vincent J ^a   Sisson, Stephen D ^a   Tidmore, William C ^a   Vom Eigen, Keith A ^a   Goodman, Steven N ^a   Lietman, Paul S ^a   Petty, Brent G ^a   Flexner, Charles ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; GENTAMICIN; LIVER ENZYME; OXACILLIN; RIFAMPICIN; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 9444283835     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00070-8     Document Type: Article

References (27)

1. 1. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Ann Intern Med. 1993;119:1017-1028.
2. 2. Bisno AL, Dismukes WE, Durack DT, et al. Antimicrobial treatment of infective endocarditis due to viridans Streptococci, Enterococci, and Staphylococci. JAMA. 1989;261:1471-1477.
3. 3. Levine DP, Fromm BS, Reddy BR. Slow clinical response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115:674-680.
4. 4. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990;34:1227-1231.
5. 5. Parker RH, Fossieck BE. Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis. Ann Intern Med. 1980;93:832-834.
6. 6. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two week combination therapy. Ann Intern Med. 1988;109:619-624.
7. 7. Rouse MS, Wilcox RM, Henry NK, et al. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother. 1990;34:273-276.
8. 8. Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1986;30:382-384.
9. 9. Fernandez-Guerrero M, Rouse M, Henry N, Wilson W. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1988;32:747-751.
10. 10. Kaatz GW, Seo SM, Barriere SL, et al. Ciprofloxacin and rifampin, alone and in combination for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989;33:1184-1187.
11. 11. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided staphylococcal endocarditis in intravenous drug users with ciprofloxacin and rifampin. Lancet. 1989;ii:1071-1073.
12. 12. Pelletier LL Jr, Petersdorf RG. Infective endocarditis: a review of 125 cases from the University of Washington Hospitals, 1963-1972. Medicine. 1977;56:287-313.
13. 13. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
14. 14. Breslow N, Day N. Statistical Methods in Cancer Research. Lyon: IARC Scientific Publications; 1980, number 32, vol. 1.
15. 15. Box G, Tiao G. Bayesian Inference in Statistical Analysis. New York: John Wiley; 1973.
16. 16. Osler W. Gulstonian lectures on malignant endocarditis - lecture III. Lancet. March 21, 1885;505-508.
17. 17. Marantz PR, Linzer M, Feiner CJ, et al. Inability to predict diagnosis in febrile intravenous drug abusers. Ann Intern Med. 1987;106:823-828.
18. 18. Samet JH, Shevitz A, Fowle J, Singer DE. Hospitalization decision in febrile intravenous drug users. Am J Med. 1990;89:53-57.
19. 19. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med. 1976;60:495-500.
20. 20. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J. Clin Microbiol. 1989;27:335-336.
21. 21. Levine DP, Crane LR, Zervos MJ. Bacteremia in narcotics addicts at the Detroit medical center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis. 1986;8:374-396.
22. 22. Tuazon CU, Sheagren JN. Increased staphylococcal carrier rate among narcotic addicts. J Infect Dis. 1974;129:725-727.
23. 23. Tuazon CU, Sheagren JN. Staphylococcal endocarditis in parenteral drug abusers: source of the organism. Ann Intern Med. 1975;82:788-790.
24. 24. Tebas P, Ruiz M, Roman F, et al. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J Infect Dis. 1991;163:204-205.
25. 25. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994;96:200-209.
26. 26. Bayer AS, Ward JI, Ginzton LE, Shapiro SM. Evaluation of new clinical criteria for the diagnosis of infective endocarditis. Am J Med. 1994;96:211-219.
27. 27. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med. 1994;121:200-206.